KIRYAT SHMONA, Israel — As you drive toward the industrial park in this border town, you pass a disquieting sight: the abandoned skeleton of a thread factory that shuttered 18 years ago. Broken glass litters the concrete floor, and behind a door condemned with “NO PASSAGE” in red spray paint, huge canisters lean against one another like dead bodies.

It’s a foreboding omen of what could happen if the world’s largest generic drug manufacturer, Teva Pharmaceutical Industries, were to pull out of this northern Israeli city.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy